Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Vasograin Plus represents a major advancement in the treatment of migraine
Subscribe To Our Newsletter & Stay Updated